Casdin Capital, LLC (hereinafter, the “Firm,” “we,” “us” or “our”), founded in 2012, is an investment advisory services firm that currently provides investment management services to its client funds. Eli Casdin is the manager and owner of the Firm and, in such capacity, has sole discretion on all investment and trading decisions. Mr. Casdin is likewise the manager of our affiliates, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC, Casdin Private Growth Equity Fund GP, LLC, and Casdin Private Growth Equity Fund II GP, LLC, which act as general partners to certain of our current client funds (the “General Partners”) The Firm currently provides its services to eight client funds, each of which is a pooled investment vehicle, or more specifically, a private investment fund, the securities of which are offered to certain qualified investors on a private placement basis: Casdin Partners, L.P., a Delaware limited partnership (“Casdin Partners”), Casdin Partners Offshore, Ltd. (“Casdin Offshore”), a Cayman Islands exempted company, Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership, which is a private pooled investment “master fund” in a master-feeder structure with Casdin Partners and Casdin Offshore (the “Master Fund”), Casdin Partners FO1-MSV, L.P., a Delaware limited partnership (“FO1”); Casdin Amplify Fund, L.P., a Delaware limited partnership (“Amplify”) (together the “ Hedge Funds”); Casdin Venture Opportunities Fund, L.P., a Delaware limited partnership (“Casdin Venture”), Casdin Private Growth Equity Fund, L.P., a Delaware limited partnership (“Casdin Private Growth”), and Casdin Private Equity Growth Fund II, L.P., a Delaware limited partnership (“Casdin Private Growth II”) (together the “PE Funds"). While we consider both Casdin Partners and Casdin Offshore as client funds, each invests substantially

all of its investable assets in the Master Fund through which we conduct these fund’s investment activities. In providing our advisory services to our client funds, we seek to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Our portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, we also have discretion to invest in certain foreign equity securities if we determine that investments in such securities could generate risk-adjusted returns for our client funds. We tailor our advisory services to the individual needs and specified investment mandates of our client funds. We adhere to the investment strategy set forth in the private placement memorandum of each client fund. We do not, however, tailor our advisory services to the individual needs or any specified investment mandates of the investors of our client funds and those investors may not impose restrictions on investing in certain securities or types of securities. We have full investment discretion in investing on behalf of our client funds and will not be required to seek approval from a client fund or such client fund’s investors with respect to a client fund’s investments. We do not participate in any wrap-fee programs. As of December 31, 2023, we have regulatory assets under management of $2,643,698,992. We manage 100% of our regulatory assets under management on a discretionary basis and none of our regulatory assets under management on a non-discretionary basis.